RIO DE JANEIRO, BRAZIL - A study suggests that the protection of CoronaVac - the principal vaccine against Covid-19 in Brazil- is lower among people infected with HIV, the virus that causes AIDS. As a result, the vaccination guideline must be maintained, including priority for booster doses among this group.
Researchers at the University of São Paulo Medical School (FMUSP) compared the protection of CoronaVac in HIV-infected and non-infected people. The study showed that after being administered the CoronaVac, a person without HIV is 3.21 times more likely to develop antibodies against Covid-19 than an individual . . .